Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead ...
50% (p=0.01) improvement on EASI score at week 8 Full data to be presented at the EAACI Congress, 12 June 2016, Vienna, Austria in a Late Breaking Oral Session DISCOVERY PARK, SANDWICH, UK, May 16, 2016 (GLOBE NEWSWIRE) -- Ziarco Pharma Ltd., a …